MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR)..

马萨诸塞州马尔伯勒，2024年9月17日/新闻专线/--波士顿科学公司（纽约证券交易所：BSX）今天宣布结束对丝绸之路医疗公司（纳斯达克：Silk）的收购，这是一家医疗器械公司，开创了一种通过称为经颈动脉血运重建（TCAR）的微创手术预防中风和治疗颈动脉疾病的新方法。

'Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their patients through our significant commercial reach,' said Cat Jennings, president, Vascular, Peripheral Interventions, Boston Scientific.

波士顿科学公司（Boston Scientific）血管、外周干预总裁凯特·詹宁斯（Cat Jennings）说：“完成这项收购，可以通过我们的重大商业影响力，将创新的TCAR平台带给更多的医生及其患者，从而加强我们的血管技术解决方案。”。

'The integration of the TCAR platform into our portfolio means we can offer a treatment option for patients suffering from carotid artery disease that can reduce the risk of stroke and lead to improved patient outcomes.'.

“将TCAR平台整合到我们的投资组合中意味着我们可以为患有颈动脉疾病的患者提供治疗选择，从而降低中风风险并改善患者预后。”

The acquisition includes a purchase price of $27.50 per share, reflecting an enterprise value of approximately $1.18 billion.i The impact to Boston Scientific adjusted earnings per share is expected to be immaterial in 2024 and 2025, and accretive thereafter. The impact to GAAP earnings per share is expected to be less accretive, or dilutive, as the case may be, due to amortization expense and acquisition-related net charges..

此次收购包括每股27.50美元的收购价格，反映出企业价值约为11.8亿美元。预计2024年和2025年对波士顿科学公司调整后每股收益的影响不大，此后会增加。由于摊销费用和收购相关的净费用，预计对GAAP每股收益的影响将不那么增值或稀释（视情况而定）。

About Boston ScientificBoston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care.

关于波士顿科学波士顿科学通过创新的医疗技术改变生活，改善世界各地患者的健康。作为全球医疗技术领导者已有45多年的历史，我们通过提供广泛的高性能解决方案来解决未满足的患者需求并降低医疗保健成本，从而推动生命科学的发展。

Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter..

我们的设备和疗法组合可帮助医生诊断和治疗复杂的心血管、呼吸、消化、肿瘤、神经和泌尿系统疾病和病症。请访问www.bostonscientific.com了解更多信息，并在LinkedIn和X（前身为Twitter）上进行连接。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like 'anticipate,' 'expect,' 'project,' 'believe,' 'plan,' 'estimate,' 'intend' and similar words.

本新闻稿包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性声明。前瞻性陈述可以用“预期”、“预期”、“项目”、“相信”、“计划”、“估计”、“打算”等词来识别。

These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding financial and business impact of the transaction and anticipated benefits of the transaction, business plans and strategy, product launches and product performance and impact.

这些前瞻性陈述是基于我们的信念、假设和估计，并使用我们当时可用的信息，并不旨在保证未来的事件或表现。这些前瞻性报表除其他外，还包括有关交易的财务和业务影响以及交易的预期收益、业务计划和战略、产品发布以及产品性能和影响的报表。

If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forward-looking statements expressed in this press release.

如果我们的基本假设不正确，或者出现某些风险或不确定性，实际结果可能与我们的前瞻性陈述所表达或暗示的预期和预测有很大差异。在某些情况下，这些因素已经影响并在未来（连同其他因素）可能影响我们实施业务战略的能力，并可能导致实际结果与本新闻稿中表达的前瞻性声明所预期的结果存在重大差异。

As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements..

因此，提醒读者不要过度依赖我们的任何前瞻性陈述。

Risks and uncertainties that may cause such differences include, among other things: economic, political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; demographic trends; the closing and integration of acquisitions, including our ability to achieve the anticipated benefits of the transaction and successfully integrate Silk Road Medical's operations; business disruptions (including disruptions in relationships with employees, customers and suppliers) following the announcement and/or closing of the transaction; intellectual property rights; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors.

可能导致此类差异的风险和不确定性包括：经济、政治、竞争、报销和监管条件；地缘政治事件；制造、分销和供应链中断以及成本增加；网络安全事件造成的中断；公共卫生突发事件或极端天气或其他气候变化相关事件造成的中断；劳动力短缺和劳动力成本增加；正在进行和未来的临床试验和市场研究结果的变化；新产品介绍和这些产品的市场接受度；我们产品的市场竞争；预期的定价环境；预期的程序量；人口趋势；；交易宣布和/或结束后的业务中断（包括与员工、客户和供应商的关系中断）；知识产权；诉讼；金融市场状况；我们业务战略的执行和效果，包括我们的成本节约和增长计划；以及我们和竞争对手做出的未来业务决策。

New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ('SEC'), which we may update in Part II, .

新的风险和不确定性可能不时出现，难以预测。所有这些因素都很难或不可能准确预测，其中许多因素超出了我们的控制范围。有关这些以及其他可能影响我们未来运营的重要风险和不确定性的进一步列表和描述，请参阅我们最近向美国证券交易委员会（“SEC”）提交的表格10-K年度报告中的第一部分第1A项-风险因素，我们可能会在第二部分中更新。

CONTACTS:Blake RouhaniMedia Relations(763) 494-2268blake.rouhani@bsci.com

联系人：Blake Rouhanimedia Relations（763）494-2268blake.rouhani@bsci.com

Jon MonsonInvestor Relations(508) 683-5450BSXInvestorRelations@bsci.com

Jon MonsonInvestor关系（508）683-5450BSXInvestorRelations@bsci.com

i Enterprise value of approximately $1.18 billion based on approximately 46.5 million fully diluted shares (or approximately $1.28 billion for 100% of the equity) and an estimated $104 million net cash position

i根据约4650万股完全稀释股份（或约12.8亿美元的100%股权）和估计的1.04亿美元净现金头寸，企业价值约为11.8亿美元

SOURCE Boston Scientific Corporation

来源波士顿科学公司